Skip to main content

Table 4 Comparison of adverse events between Endostar combined with chemotherapeutic agents versus chemotherapeutic agents alone

From: Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis

Study Myelotoxicity (%) Nausea/vomiting (%) Liver and renal injury (%) Arrhythmia (%) Fever (%)
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
Li G 2011 [17] 4 (13.3) 4 (13.3) 4 (13.3) 3 (10) 1 (3.3) 0 (0) 7 (23.3) 6 (20)
Yao Q 2012 [19] 12 (40) 10 (30) 5 (16.7) 5 (16.7)
Zheng Q 2013 [20] 17 (28.3) 16 (26.6) 10 (16.7) 5 (8.3)
Kang Y 2013 [21] 11 (24.4) 10 (22.2) 15 (25) 15 (25) 4 (8.8) 3 (6.6) 2 (3.3) 0 (0) 7 (15.5) 5 (11.1)
Wen J 2014 [22] 22 (73.3) 20 (66.6) 6 (20) 4 (13.3) 5 (16.6) 1 (3.3)
Yue G 2014 [23] 10 (23.3) 8 (18.6) 7 (16.3) 6 (14)
Tu J 2014 [24] 7 (15.5) 9 (20) 9 (20) 9 (20) 2 (4.4) 2 (4.4) 2 (4.4) 1 (2.2)
Xu J 2014 [25] 14 (40) 9 (25.7) 4 (11.4) 2 (5.7) 2 (5.7) 1 (2.8) 1 (2.8) 1 (2.8) 1 (2.8) 0 (0)
Hu X 2015 [27] 7 (16.3) 5 (12.2) 26 (60.4) 20 (48.7) 5 (11.6) 5 (12.1) 3 (6.9) 3 (7.3) 5 (11.6) 5 (12.1)
  P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
  1. Values are given as number of patients (%). Group 1 = Endostar combined with chemotherapeutic agents; Group 2 = chemotherapeutic agents alone